Abbott Laboratories said Thursday it has agreed with privately-held Bigfoot Biomedical to develop and commercialize patient diabetes management systems, integrating Abbott’s glucose sensing technology with Bigfoot’s insulin delivery systems. No terms disclosed. The company said the results of the collaboration should make managing diabetes less difficult for patients.
Abbott will provide Bigfoot with the next generation of glucose sensing technology, which Bigfoot will utilize in insulin delivery systems that do not require a “fingerstick” calibration of a glucose sensor. Abbott said Bigfoot has both injection and infusion pump-based insulin delivery systems in development, that utilize intuitive design, web-connectivity, smartphone technology and automation to adjust dosing. Abbott said Bigfoot anticipates initiating a pivotal trial of the new diabetes treatment systems.